Literature DB >> 8070929

Concentrations of ampicillin and sulbactam in serum and in various compartments of the respiratory tract of patients.

A Wildfeuer1, K H Rühle, P L Bölcskei, M Springsklee.   

Abstract

After infusion of 2 g ampicillin and 1 g sulbactam the concentrations of these two beta-lactams were determined in serum and various compartments of the respiratory tract of 22 patients. About 30 min after the end of the infusion in 15 patients the mean serum concentration of ampicillin was 97 +/- 9.5 mg/l and of sulbactam 37.6 +/- 3.8 mg/l; in the biopsy samples of bronchial mucosa the concentration of ampicillin was 38.6 +/- 7.2 mg/kg and of sulbactam 28.1 +/- 5.2 mg/kg; in bronchial fluid the concentration of ampicillin was 0.6 +/- 0.1 mg/l and of sulbactam 0.3 +/- 0.1 mg/l (n = 15). In a further seven patients serum and pleural empyema samples were analysed and compared. The mean values of Cmax attained 1 to 2 h after the end of the infusion in pleural empyema were 7.6 +/- 3.1 mg/l and 6.2 +/- 1.6 mg/l for ampicillin and sulbactam, respectively. The two beta-lactams were eliminated markedly more slowly from empyema than from serum. These results show that ampicillin and sulbactam rapidly penetrate into various compartments of the respiratory tract and reach therapeutically active concentrations. The ratio of their concentrations (2:1) is largely the same as that in serum. The pharmacokinetic data therefore support the use of ampicillin/sulbactam in the perioperative prophylaxis and the treatment of bacterial infections of the lower respiratory tract.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8070929     DOI: 10.1007/bf01739027

Source DB:  PubMed          Journal:  Infection        ISSN: 0300-8126            Impact factor:   3.553


  5 in total

Review 1.  The site concentrations of antimicrobial agents in the lung.

Authors:  D Honeybourne; D R Baldwin
Journal:  J Antimicrob Chemother       Date:  1992-09       Impact factor: 5.790

2.  Sulbactam/ampicillin: in vitro spectrum, potency, and activity in models of acute infection.

Authors:  J A Retsema; A R English; A Girard; J E Lynch; M Anderson; L Brennan; C Cimochowski; J Faiella; W Norcia; P Sawyer
Journal:  Rev Infect Dis       Date:  1986 Nov-Dec

3.  Concentrations of sulbactam/ampicillin in serum and lung tissue.

Authors:  U Frank; E Schmidt-Eisenlohr; A Joos-Württemberger; J Hasse; F Daschner
Journal:  Infection       Date:  1990 Sep-Oct       Impact factor: 3.553

4.  Pharmacokinetics of ampicillin and sulbactam in patients undergoing heart surgery.

Authors:  A Wildfeuer; V Müller; M Springsklee; H G Sonntag
Journal:  Antimicrob Agents Chemother       Date:  1991-09       Impact factor: 5.191

5.  [Sulbactam/ampicillin in comparison with cefuroxime for infections of the lower respiratory tract. Results of a prospective, randomized comparative study].

Authors:  C D Schwigon; R Cuhorst; M Gabor; J Zinndorf; M Springsklee
Journal:  Med Klin (Munich)       Date:  1993-01-15
  5 in total
  5 in total

1.  Postpneumonic empyema in childhood.

Authors:  N Belet; S Uysal; E Bernay; N Gurses
Journal:  Indian J Pediatr       Date:  2001-01       Impact factor: 1.967

2.  Penetration of ampicillin and sulbactam into human epididymis and testis.

Authors:  T Klotz; M Braun; A Wildfeuer; U Engelmann
Journal:  Infection       Date:  1996 Sep-Oct       Impact factor: 3.553

3.  [Ampicillin and sulbactam concentrations in the irradiated mandible after oral squamous cell cancer].

Authors:  H Heibel; M Scheer; T Reuther; M Hahn; R Trittler; H Egle; K Kümmerer; A C Kübler
Journal:  Mund Kiefer Gesichtschir       Date:  2005-07

4.  Ampicillin/sulbactam in elderly patients with community-acquired pneumonia.

Authors:  J Majcher-Peszynska; M Loebermann; S Klammt; S Frimmel; R G Mundkowski; T Welte; E C Reisinger; B Drewelow
Journal:  Infection       Date:  2013-08-01       Impact factor: 3.553

5.  Outcomes of Adjunctive Therapy with Intravenous Cefoperazone-Sulbactam for Ventilator-Associated Pneumonia Due to Carbapenem-Resistant Acinetobacter baumannii.

Authors:  Siripen Kanchanasuwan; Narongdet Kositpantawong; Kamonnut Singkhamanan; Thanaporn Hortiwakul; Boonsri Charoenmak; Nwabor Ozioma F; Yohei Doi; Sarunyou Chusri
Journal:  Infect Drug Resist       Date:  2021-03-29       Impact factor: 4.003

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.